Cancer statistics, 2024
By R. Siegel, Angela N Giaquinto, A. Jemal. Ca, 2024
10,166 citations recorded by the source corpus.
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2020) and mortality data collected by the National Center for Health Statistics (through 2021). In 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both the adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers. Incidence rates increased during 2015–2019 by 0.6%–1% annually for breast, pancreas, and uterine corpus cancers and by 2%–3% annually for prostate, liver (female), kidney, and human papillomavirus‐associated oral cancers and for melanoma. Incidence rates also increased by 1%–2% annually for cervical (ages 30–44 years) and colorectal cancers (ages <55 years) in young adults. Colorectal cancer was the fourth‐leading cause of cancer death in both men and women younger than 50 years in the late‐1990s but is now first in men and second in women. Progress is also hampered by wide persistent cancer disparities; compared to White people, mortality rates are two‐fold higher for prostate, stomach and uterine corpus cancers in Black people and for liver, stomach, and kidney cancers in Native American people. Continued national progress will require increased investment in cancer prevention and access to equitable treatment, especially among American Indian and Alaska Native and Black individuals.
Subfields: Epidemiology, Oncology
View Paper: https://www.semanticscholar.org/paper/543aef9f57808495d12242bce3474fb80d01a4ad
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Antonia Resag
- Luise Rupp
- Mechthild Krause
- Annett Linge
- M. Schmitz
- Ioana Plesca
- I. Benešová
- Rebecca Rothe
Citations in the corpus
- Transcriptomic profile induced by calcitriol in CaSki human cervical cancer cell line (2025, unknown): “Cervical cancer, predominantly affecting middle-aged women in underdeveloped regions, ranks as the fourth most prevalent cancer in women globally, following breast, lung, and colorectal cancers [1].”
- Type I conventional dendritic cells and CD8+ T cells predict favorable clinical outcome of head and neck squamous cell carcinoma patients (2024, methodology): “…cell in fi ltrates were compared between patient subgroups strati fi ed by clinicopathological characteristics (tumor grading, p16 status, hypoxia) for the whole HNSCC cohort, as well as for HPV-, and hypoxia-associated subcohorts (clinical characteristics of subcohorts in Supplementary Tables 3, 4).”